Merck CEO says breakthrough cancer vaccine will be made faster

• The personalized cancer vaccine currently takes six weeks from tumor sequencing to delivery, a timeline Merck aims to reduce while maintaining the 'very tight science' of the complex manufacturing process
• Merck is testing the vaccine across multiple cancer types including melanoma, non-small cell lung cancer, bladder cancer, and renal cell carcinoma, with Davis noting the technology moves toward 'talking about a cure'
• The new facility opening is part of Merck's strategy to prepare for Keytruda's patent expiration in 2028-2029, as the company pursues acquisitions and develops new drug formulations to offset revenue loss from one of the world's top-selling drugs

Market Summary: Merck's Cancer Vaccine Manufacturing and Strategic Developments

Key Developments:

Merck CEO Rob Davis announced the company expects to accelerate production of its breakthrough personalized cancer vaccine, developed in partnership with Moderna. The current manufacturing timeline of six weeks—from tumor sequencing to hospital delivery—is expected to shorten over time, though Davis emphasized immediate focus remains on ensuring adequate supply for market launch.

Product Details:

The personalized vaccine targets specific mutations in individual patient tumors and is combined with Merck's blockbuster immunotherapy Keytruda. Recent late-stage trial results released in August showed promising outcomes in melanoma patients. The companies are expanding clinical trials to include non-small cell lung cancer, bladder cancer, and renal cell carcinoma.

Infrastructure Investment:

Merck officially opened a new 120,000-square-foot research facility called Advance in West Point, Pennsylvania, featuring advanced robotic systems and AI capabilities designed to streamline biological sample analysis and accelerate drug development.

Strategic Context:

The developments come as Merck prepares for Keytruda's patent expiration—the core U.S. compound patent expires December 2028, with secondary patents extending to 2029 and beyond. Merck has implemented a multi-layered strategy including $15 billion in external acquisitions over five years to build its pipeline.

The FDA approved a subcutaneous version of Keytruda in September 2025, though a Dutch court blocked sales across eight European countries following patent infringement claims by Halozyme Therapeutics. Halozyme has also sued Merck in the U.S. over 15 patents.

Pipeline: New launches include Winrevair for rare lung disease and cholesterol-lowering pill Lipfendra, approved last month.